Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2018

01-07-2018 | Melanomas

Revolutionary Advances in Immunotherapy for Melanoma Are Coming into the Surgical Arena: Are We Ready?

Author: Charles M. Balch, MD, FACS, FASCO

Published in: Annals of Surgical Oncology | Issue 7/2018

Login to get access

Excerpt

In the past decade, powerful new immunotherapy agents have demonstrated remarkable improvements in survival of patients with many histological types of stage IV cancer, as first demonstrated in metastatic melanoma and reported in 2010.1 With a new understanding of the immune system and a growing portfolio of powerful immunotherapy agents, survival rates in stage IV melanoma patients have dramatically increased from a historical median survival of 2–9 months, to a remarkable median survival exceeding 24 months, with approximately 20% of patients remaining in remission after 8 years.2–5 …
Literature
1.
2.
Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315(15):1600–1609.CrossRefPubMed
3.
Callahan MK, Kluger H, Postow MA, et al. Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study. J Clin Oncol. 2018;36(4):391–398.CrossRefPubMed
4.
McDermott D, Lebbé C, Hodi FS, et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 2014;40(9):1056–1064.CrossRefPubMed
5.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356.CrossRefPubMedPubMedCentral
6.
7.
8.
9.
Faries MB, Mozzillo N, Kashani-Sabet M, et al. Long-term survival after complete surgical resection and adjuvant immunotherapy for distant melanoma metastases. Ann Surg Oncol. 2017;24(13):3991-–4000.CrossRefPubMed
10.
Andtbacka RHI, Kaufman KL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2770–2788.CrossRef
11.
Andtbacka RHI, Ross M, Puzanov I, et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann Surg Oncol. 2016;23(13):4169–4177.CrossRefPubMedPubMedCentral
12.
IMLYGIC (talimogene laherparepvec) Prescribing Information. October 2015. Amgen Inc.: Thousand Oaks, CA.
13.
Chesney J, Puzanov I, Collichio F, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2017;35. [Epub ahead of print].
14.
Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109–1119.CrossRefPubMed
15.
Balch CM. Presidential address: Surgical oncology in the 21st century. Arch Surg. 1992;127:1272–1277.CrossRefPubMed
Metadata
Title
Revolutionary Advances in Immunotherapy for Melanoma Are Coming into the Surgical Arena: Are We Ready?
Author
Charles M. Balch, MD, FACS, FASCO
Publication date
01-07-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 7/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6516-4

Other articles of this Issue 7/2018

Annals of Surgical Oncology 7/2018 Go to the issue

Bone and Soft Tissue Sarcomas

Clinicopathological Features and Prognosis of Primary GISTs with Tumor Rupture in the Real World

Breast Oncology

Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer

Gastrointestinal Oncology

Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer

Pancreatic Tumors

FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma

Melanomas

The Effect of Temperature and Perfusion Time on Response, Toxicity, and Survival in Patients with In-transit Melanoma Metastases Treated with Isolated Limb Perfusion

Melanomas

Adjuvant Therapy in the Treatment of Melanoma